Brief: Jaguar Completes Enrollment In Phase 3 Trial Of Crofelemer
09/05/2023 13:39
May 9 (Reuters) - Jaguar Health Inc JAGX.O :
* JAGUAR COMPLETES ENROLLMENT IN ITS PIVOTAL PHASE 3
ONTARGET
TRIAL OF CROFELEMER FOR PROPHYLAXIS OF CANCER THERAPY-RELATED
DIARRHEA
* JAGUAR HEALTH INC - PRIMARY ENDPOINT BASED ON PATIENT
REPORTED
OUTCOMES FROM STUDY EXPECTED IN OCTOBER 2023
Source text for Eikon: ID:
Further company coverage: JAGX.O
((Reuters.Briefs@thomsonreuters.com;))